ZENAPAX VERSUS ANTI LYMPHOCYTE GLOBULIN PROPHYLAXIS IN IMMUNOLOGICALLY HIGH-RISK GROUP OF RENAL ALLOGRAFT RECIPIENTS

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

POURFARZIANI V.; LESANPEZESHKI M.; EYN ELAHI BEHZAD

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: KOWSAR MEDICAL JOURNAL Year:2007 | Volume:12 | Issue:1 Page(s): 69-73

Download Full-Text

Persian Verion

View:

1,940

Download:

Cites:

Information Journal Paper

Title

ZENAPAX VERSUS ANTI LYMPHOCYTE GLOBULIN PROPHYLAXIS IN IMMUNOLOGICALLY HIGH-RISK GROUP OF RENAL ALLOGRAFT RECIPIENTS

Author(s)

POURFARZIANI V. | LESANPEZESHKI M. | EYN ELAHI BEHZAD | Issue Writer Certificate

Keywords

REJECTIONQ3

TRANSPLANTQ3

SURVIVALQ2

OUTCOMEQ3

ATNQ3

Abstract

Introduction: We studied the effect of Zenapax induction therapy compared with Anti Lymphocyte Globulin (ALG) induction therapy in high-risk recipients.Matherials and Methods: Twenty five re-transplanted patients as high-risk recipients were randomized into two groups. Group 1 (n=11) received Zenapax prophylaxis and group 2 (n=14) received ALG prophylaxis. Baseline immunosuppression consisted of cyclosporine, prednisolone and mycophenolate mofetil. All patients were followed one year after TRANSPLANTation.Results: Recipients’ sex, age, etiology of end stage renal disease (ESRD), PRA serostatus, as well as donors’ sex and age were comparable between two groups. All patients received re-transplantations from unrelated living donors. After TRANSPLANTation, episodes of acute REJECTION were observed in 8 patients of ALG group vs. only 2 patients in Zenapax group (P=0.04). There was no difference regarding to rate of acute tubular necrotic (ATN) between two groups. One-year graft SURVIVAL was 100% in Zenapax group vs. 68.7% in ALG group (P=0.05). Anemia occurred in one patient in Zenapax group vs. five patients in ALG group (P=0.04). Five cases of leukopenia and four cases of thrombocytopenia were observed in ALG group whereas none patients in Zenapax group experienced these two complications (P=0.007 and P=0.02, respectively). Rate of cytomegalovirus (CMV) infection was similar in the two groups.Conclusions: In conclusion, this study suggested that Zenapax prophylaxis yielded lower complications. In addition, it seems Zenapax can improve graft OUTCOME and reduces incidence of the acute REJECTION episodes in high-risk kidney recipients.

Cites

No record.

References

No record.

Cite

APA: Copy

POURFARZIANI, V., LESANPEZESHKI, M., & EYN ELAHI, BEHZAD. (2007). ZENAPAX VERSUS ANTI LYMPHOCYTE GLOBULIN PROPHYLAXIS IN IMMUNOLOGICALLY HIGH-RISK GROUP OF RENAL ALLOGRAFT RECIPIENTS. KOWSAR MEDICAL JOURNAL, 12(1), 69-73. SID. https://sid.ir/paper/32844/en

Vancouver: Copy

POURFARZIANI V., LESANPEZESHKI M., EYN ELAHI BEHZAD. ZENAPAX VERSUS ANTI LYMPHOCYTE GLOBULIN PROPHYLAXIS IN IMMUNOLOGICALLY HIGH-RISK GROUP OF RENAL ALLOGRAFT RECIPIENTS. KOWSAR MEDICAL JOURNAL[Internet]. 2007;12(1):69-73. Available from: https://sid.ir/paper/32844/en

IEEE: Copy

V. POURFARZIANI, M. LESANPEZESHKI, and BEHZAD EYN ELAHI, “ZENAPAX VERSUS ANTI LYMPHOCYTE GLOBULIN PROPHYLAXIS IN IMMUNOLOGICALLY HIGH-RISK GROUP OF RENAL ALLOGRAFT RECIPIENTS,” KOWSAR MEDICAL JOURNAL, vol. 12, no. 1, pp. 69–73, 2007, [Online]. Available: https://sid.ir/paper/32844/en

Related Journal Papers